Handelsbanken Fonder AB Purchases 10,100 Shares of Moderna, Inc. $MRNA

Handelsbanken Fonder AB raised its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 10.9% during the 3rd quarter, Holdings Channel reports. The fund owned 102,900 shares of the company’s stock after purchasing an additional 10,100 shares during the period. Handelsbanken Fonder AB’s holdings in Moderna were worth $2,658,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of MRNA. Banco Santander S.A. increased its position in Moderna by 22.1% in the third quarter. Banco Santander S.A. now owns 215,894 shares of the company’s stock worth $5,577,000 after purchasing an additional 39,056 shares during the last quarter. Mufg Securities Americas Inc. grew its stake in shares of Moderna by 23.8% in the 3rd quarter. Mufg Securities Americas Inc. now owns 9,338 shares of the company’s stock worth $241,000 after buying an additional 1,796 shares in the last quarter. AXQ Capital LP increased its holdings in shares of Moderna by 115.4% in the 3rd quarter. AXQ Capital LP now owns 21,749 shares of the company’s stock worth $562,000 after buying an additional 11,650 shares during the last quarter. Telemark Asset Management LLC bought a new position in shares of Moderna in the 3rd quarter valued at about $12,915,000. Finally, NEOS Investment Management LLC lifted its holdings in shares of Moderna by 52.2% in the 3rd quarter. NEOS Investment Management LLC now owns 38,662 shares of the company’s stock valued at $999,000 after acquiring an additional 13,258 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Stock Down 5.7%

Shares of NASDAQ MRNA opened at $49.83 on Wednesday. The stock has a 50 day moving average price of $41.78 and a 200 day moving average price of $31.72. The firm has a market capitalization of $19.68 billion, a price-to-earnings ratio of -6.85 and a beta of 1.29. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $55.20. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.22 and a current ratio of 3.29.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, February 13th. The company reported ($2.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.79) by $0.68. The business had revenue of $678.00 million during the quarter, compared to analyst estimates of $611.14 million. Moderna had a negative return on equity of 30.15% and a negative net margin of 145.16%.Moderna’s revenue was down 33.2% on a year-over-year basis. During the same period in the previous year, the company posted ($2.91) EPS. Sell-side analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on MRNA shares. UBS Group restated a “neutral” rating and set a $36.00 price objective on shares of Moderna in a research report on Monday, February 16th. Sanford C. Bernstein restated a “market perform” rating and issued a $45.00 target price on shares of Moderna in a report on Tuesday, February 17th. Berenberg Bank set a $28.00 target price on Moderna in a research report on Monday, November 17th. Citigroup reiterated a “neutral” rating on shares of Moderna in a report on Monday, February 16th. Finally, Leerink Partners restated an “underperform” rating on shares of Moderna in a report on Friday, January 30th. Two research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $32.33.

Insider Activity

In other news, President Stephen Hoge sold 160,009 shares of the stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the transaction, the president directly owned 1,457,427 shares in the company, valued at approximately $71,180,734.68. This trade represents a 9.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Noubar Afeyan sold 23,853 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $29.48, for a total transaction of $703,186.44. Following the completion of the transaction, the director directly owned 3,924 shares of the company’s stock, valued at $115,679.52. This trade represents a 85.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 184,366 shares of company stock worth $8,531,936. 10.90% of the stock is owned by company insiders.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: EU drug advisers (CHMP) recommended Moderna’s COVID‑19 + flu combo vaccine (mCombriax), which accelerates a likely EMA approval and supports near‑term commercial upside for seasonal respiratory vaccines. Moderna’s dual Covid-flu vaccine poised for EMA approval on positive CHMP take
• Positive Sentiment: Moderna announced a settlement that the company says resolves worldwide Arbutus/Genevant litigation and, importantly, removes future royalty obligations tied to Spikevax and other infectious‑disease programs — reducing long‑term royalty risk and clearing an overhang on its vaccine and pipeline commercialization. Moderna Resolves Global Patent Litigation with Arbutus/Genevant
• Neutral Sentiment: Management presentation at the TD Cowen Health Care conference (transcript) reiterated pipeline progress and strategy (oncology, combo respiratory vaccines and other mRNA programs). These updates keep the long‑term narrative intact but are incremental versus the settlement/regulatory headlines. Moderna Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Neutral Sentiment: Analyst/opinion pieces are re‑examining Moderna’s valuation and long‑term thesis (oncology programs, cash runway). These note large upside if cancer vaccine trials succeed but emphasize binary clinical risk — useful context but not an immediate catalyst. Moderna Stock (MRNA): Is It a Buy Now? 7 Questions After the Crash
• Negative Sentiment: Moderna agreed to a settlement structure that will require a cash payment and an expected Q1 charge (reported at $950M upfront with the possibility of up to $2.25B total depending on appeal outcomes). That creates an immediate earnings hit, reduces cash balances and injected downside pressure into the stock despite the removal of future royalties. Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant
• Negative Sentiment: Coverage also notes Moderna will appeal a District Court ruling (Section 1498) and that additional contingent payments could hinge on the Federal Circuit outcome — leaving residual legal/financial uncertainty despite the settlement agreement. Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.